Erasca Inc

ERAS remains in a Stage 2 advancing regime with clear higher-highs and higher-lows above rising moving averages, supported by an active Lockout Rally. Price is holding a shallow pullback into the rising 9EMA and 20EMA support zone, and short-term timing favors buying the pullback for momentum continuation.

• ↑ERAS-0015 targets RAS/MAPK cancers with strong clinical promise
• ↑13F ownership shows significant institutional backing
• ↓Securities class action caused 48% drop and $2.8B market loss